Skip to main content
Premium Trial:

Request an Annual Quote

BioView, Ruby Nanomed Form Circulating Tumor Cell Analysis Partnership

NEW YORK — BioView and Ruby Nanomed said on Thursday that they have partnered on the development of a circulating tumor cell (CTC) analysis technology for clinical use.

Under the terms of the alliance, the companies will integrate BioView's Duet imaging system with Ruby Nanomed's Rubychip microfluidic device for CTC isolation, enabling the automatic classification of cancer cells within the device with the goal of facilitating patient monitoring and stratification. The work is being funded by Spanish nonprofit La Caixa Foundation.

Additional terms were not disclosed.

The companies said that the integrated product will initially be available for research use only with clinical trials aimed at securing regulatory approvals starting in 2022.

In 2014, BioView's Duet system received US Food and Drug Administration clearance for use in detecting rearrangements involving the ALK gene in non-small cell lung cancer samples. Earlier this year, the Israeli company and collaborators at Angle presented data on the integration of Duet with Angle's Parsortix cell-sorting platform.

Braga, Portugal-based Ruby Nanomed was founded in 2018 as a spinout of the International Iberian Nanotechnology Laboratory.